Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

NCT06639256 is registered in ClinicalTrials.gov with Sichuan Huiyu Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06639256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
Lead sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 24, 2024
Completion date
October 26, 2027
Enrollment
258 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, safety, tolerability